07 May 2019
Visiongain has launched a new pharma report mRNA Vaccines and Therapeutics Market Report: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy.
mRNA-based drugs have emerged as a highly attractive new class of biologics that encodes any protein of interest directly in vivo. The last two decades have been crucial in generating interest in various RNA based technologies. Clinical and preclinical trials in the field have led to positive responses facilitating increasing funding and investment by major pharmaceutical and biopharmaceutical companies. Clinical trials have proven that mRNA vaccines provide long lasting immune responses and are safe in animal and human models.
The lead analyst of the report commented "The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.
Effective and safe delivery remains a major challenge despite the potential of RNA therapy. High cost of development and stringent process of regulatory approvals might also restrain the mRNA vaccines and therapeutics market."
Leading companies featured in the report include Argos Therapeutics, Inc., BioNTech AG. CureVac AG, eTheRNA Immunotherapies, ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamo Therapeutics, Inc., Tiba Biotech, Translate Bio, Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.